Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | DREAMM-3: belantamab mafodotin vs pom/dex for R/R myeloma

Katja Weisel • 31 May 2020
EHA 2020
Multiple Myeloma Antibodies Belantamab mafodotin Pomalidomide
DREAMM-3 GMMG-CONCEPT

Katja Weisel, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses DREAMM-3, a Phase III, open-label, randomized study of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone (pom/dex) in relapsed/refractory (R/R) multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Katja Weisel

DREAMM-3: safety of belantamab mafodotin versus pom/dex in patients with R/R myeloma 1:02
DREAMM-3: safety of belantamab mafodotin versus pom/dex in patients with R/R myeloma
Katja Weisel • 3 Jun 2023
Ocular adverse events with ADCs 1:28
Ocular adverse events with ADCs
Katja Weisel • 10 Sep 2021
ADCs for the treatment of myeloma 3:02
ADCs for the treatment of myeloma
Katja Weisel • 10 Sep 2021
MRD: from clinical trials to clinical practice 1:43
MRD: from clinical trials to clinical practice
Katja Weisel • 10 Sep 2021

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals